



# Ehlers-Danlos: a invisible disease

Nikita Meylan

# What Is Ehlers-Danlos?

Group of inherited connective tissue disorder

- Affect collagen and extracellular matrix (ECM)

Known since 1901

3 main features:


- Joint hypermobility
- Skin hyperextensibility
- Tissue fragility


Composed of 13 different subtypes

- Hypermobile-type Ehlers-Danlos syndrome (hEDS)

Prevalence of the disease

- 1/5000 people worldwide
- Recent study in Wales, UK: 1/500





# Collagen

Triple helical conformation made of 3 alpha chains.

Collagen fibrils made by self-assembly

Cross-linking occurs between adjacent tropocollagen.

# Why is collagen important?


Table 1: Types of collagen

Type	Gene name	Chains	Characteristic features	Tissue distribution	Major function
I	Col1A1	$\alpha 1(I)$ 3	Most abundant collagen	Abundant in skin, bone dentin cementum, tendons, ligaments and most connective tissue	Provides tensile strength to connective tissue
	Col1A2	$\alpha 1(I)$ 2			
II	Col2A1	$\alpha 1(II)$ 3	Forms heterofibrils with colix	Cartilage, vitreous humor, intervertebral disk	Provides tensile strength to connective tissue
III	Col3A1	$\alpha 1(III)$ 3	Abundant in elastic tissue	Embryonic connective tissue, pulp, skin, blood vessels, lymphoid tissue	Provides tensile strength to connective tissue
V	Col5A1	$\alpha 1(V)$ 2	Forms the core of Type I fibrils.	Basal lamina, blood vessels, ligaments, skin, dentin, periodontal tissues	Provides tensile strength to connective tissue
	Col5A2	$\alpha 2(V)$	Binds to DNA heparin sulfate, thrombospondin, heparin, and insulin		
XI	Col1A1	$\alpha 1XII$	Forms core of Type II fibrils	Cartilage, vitreous humor, placenta	Provides tensile strength, controlling lateral growth of Type II fibrils
	Col1A2	$\alpha 2XII$			
		$\alpha 3XII$			
XXIV	Col24A1	$\alpha 1(XXIV)$ 3	Displays structural features unique to invertebrates fibrillar collagen	Bone cornea	Regulation of Type I fibrinogenesis
XXVII	Col27 A1	$\alpha 1(XXVII)$ 3	Presence of triple helix imperfection	Cartilage, eye, ear, lungs	Association of Type II fibrils
VI	COL6A1, A2, A3	$\alpha 1(VI)$ $\alpha 2(VI)$ $\alpha 3(VI)$	Highly disulfide crosslinked	Ligaments, skin, placenta, cartilage	Bridging between cells and matrix
XII	COL13A1	$\alpha 1(XIII)$ 3	Single transmembrane domain	Epidermis, hair follicle, cell surface	Cell matrix, cell to cell adhesion
XXV	COL25A1	$\alpha 1(XXV)$ 3	Extracellular domain deposited in $\beta$ amyloid plaques	Neurons	Neuron adhesion
XV	COL15A1	$\alpha 1(XV)$ 3	Contains antiangiogenic factor	Epithelial and endothelial basement membranes	Stabilizes skeletal muscle cells and microvessels
IX	COL9A1	$\alpha 1(IX)$	Interacts with glycosaminoglycans in cartilage	Cartilage, vitreous humor	Attaches functional groups to surface of Type II fibrils
XIV	COL14A1	$\alpha 1(XIV)$ 3	Associated with Type I	Widespread in many connective tissue	Modulates fibril interactions
XXVI	COL26A1	$\alpha 1(XXVI)$ 3	Disulfide bonds are made into N-terminal noncollagenous domain	Developing and adult testis and ovary	Unknown
IV	COL4A1	$\alpha 1(IV)$ 2	Interaction with Type IV, laminin, nidogen, integrin	Basal laminae	Structural network of basal lamina together with proteoglycans and laminin, nidogen, integrin
VIII	COLBA1	$\alpha 1(VIII)$ 2		Cornea, endothelium	Tissue support, porous network
X	COL10A1	$\alpha 1(X)$ 3		Hypertrophic zone of cartilage growth plate	Calcium binding
VII	COL7A1	$\alpha 1(VII)$ 3	Forms bundles made of dimmers anchored in anchoring plaques and basal lamina	Epithelium (skin, mucosa)	Strengthens epithelial-connective tissue junction


- Form the major part of ECM
- Most abundant protein in the body
- Different types of collagen
- Help maintain the structural integrity of tissues

# A constellation of symptoms

Neurological



Chiari Malformation




Cervical Instability



Tendon or Ligament Tears




Easy Bruising



Hernias



MCAS




Pelvic Prolapse



Delayed Wound Healing


Pro




Mitral Valve Prolapse



POTS




Hypermobility



Gastroparesis



Joint Dislocations




Abnormal Scarring

- Unlike other EDS, there is no genetic test for hEDS.
- 3 criteria:
  1. Assess generalized joint hypermobility
    - 5-Points quizz: at least 2 positive answers


## The Brighton Score

The Brighton Score assesses joint hypermobility.


A positive score is 5 out of 9 for adults; 6 out of 9 for children. Joint hypermobility is a symptom of hypermobile Ehlers Danlos Syndrome, but a diagnosis requires additional symptoms.



One point for each arm  
The elbow can bend backwards beyond 10°.



One point for each leg  
The knee can bend backwards beyond 10°.



One point for each hand  
The little finger can be pulled back beyond 90°.



One point for each hand  
The thumb can be pulled down to touch the forearm.



One point  
The palms can be placed flat on the floor without bending the knees.

1. Can you now (or could you ever) place your hands flat on the floor without bending your knees?
2. Can you now (or could you ever) bend your thumb to touch your forearm?
3. As a child, did you amuse your friends by contorting your body into strange shapes or could you do the splits?
4. As a child or teenager did your shoulder or kneecap dislocated on more than one occasion?
5. Do you consider yourself double-jointed?



2. Fullfilled 2 or more of the following:
  - At least 5 of systemic manifestations
  - Positive family history
  - Muscoskeletal complications
  
3. Fullfilled all of the following:
  - Absence of unusual skin fragility
  - Exclusion of other connective tissue disorders
  - Exclusion of alternate diagnosis that include joint hypermobility
  
- Biopsy possible but not always conluant

# Challenges



# The role of genetics

**Table I.** Clinical Classification of the Ehlers-Danlos Syndromes, Inheritance Pattern, and Genetic Basis

	Clinical EDS subtype	Abbreviation	IP	Genetic basis	Protein						
1	Classical EDS	cEDS	AD	Major: <i>COL5A1</i> , <i>COL5A1</i> Rare: <i>COL1A1</i> c.934C>T, p.(Arg312Cys)	Type V collagen Type I collagen	5	Hypermobile EDS	hEDS	AD	Unknown	Unknown
						6	Arthrochalasia EDS	aEDS	AD	<i>COL1A1</i> , <i>COL1A2</i>	Type I collagen
						7	Dermatosparaxis EDS	dEDS	AR	<i>ADAMTS2</i>	<i>ADAMTS2</i>
						8	Kyphoscoliotic EDS	kEDS	AR	<i>PLOD1</i> <i>FKBP14</i>	LH1 <i>FKBP22</i>
2	Classical-like EDS	cIEDS	AR	<i>TNXB</i>	Tenascin XB	9	Brittle Cornea syndrome	BCS	AR	<i>ZNF469</i>	<i>ZNF469</i>
3	Cardiac-valvular	cvEDS	AR	<i>COL1A2</i> (biallelic mutations that lead to <i>COL1A2</i> NMD and absence of pro $\alpha$ 2(I) collagen chains)	Type I collagen	10	Spondyloplastic EDS	spEDS	AR	<i>PRDM5</i> <i>B4GALT7</i>	<i>PRDM5</i> $\beta$ 4GalT7
4	Vascular EDS	vEDS	AD	Major: <i>COL3A1</i> Rare: <i>COL1A1</i> c.934C>T, p.(Arg312Cys) c.1720C>T, p.(Arg574Cys) c.3227C>T, p.(Arg1093Cys)	Type III collagen Type I collagen	11	Musculocontractural EDS	mcEDS	AR	<i>B3GALT6</i> <i>SLC39A13</i> <i>CHST14</i>	$\beta$ 3GalT6 ZIP13 D4ST1
						12	Myopathic EDS	mEDS	AD or AR	<i>DSE</i> <i>COL1A1</i>	<i>DSE</i> Type XII collagen
						13	Periodontal EDS	pEDS	AD	<i>C1R</i> <i>C1S</i>	<i>C1r</i> <i>C1s</i>

IP, inheritance pattern; AD, autosomal dominant; AR, autosomal recessive, NMD, nonsense-mediated mRNA decay.

# Potential gene mutation candidates for hEDS



COL3A1



LZTS1



TPSAB1




TNXB

# Candidate 1:

- Mutation observed in one family with hEDS (5 individus)
- Cultured fibroblasts showed reduced secretion of overmodified type III collagen.
- Usually associated with Vascular-type EDS
- Too few mutations in this region were studied and no other report of similar case.



COL3A1




# Candidate 2:



LZTS1

- Chromosome locus identified on 8p22-8p21.1, in multigenerational Belgian family (13 individus)
- Culture of fibroblast and RNA sequencing by genome wide linkage and whole exome sequencing

D8S254  
D8S261  
D8S258  
D8S1771  
D8S1820



cDNA	Protein	SIFT	PolyPhen-2	Align GVGD	Mutation Taster
c.633C>A	p.(His211Gln)	Tolerated	Probably damaging	C0	Disease-causing
c.49C>G	p.(His17Asp)	Tolerated	Probably damaging	C0	Disease-causing
c.1585C>T	p.(Arg529Trp)	Deleterious	Probably damaging	C0	Disease-causing
c.749C>A	p.(Ser250*)	—	—	—	—



- Role in modulating gene transcription
- No conclusive evidence of exact function.

# Candidate 3:



TPSAB1


- Mutation observed in 35 families (96 individuals)
- Culture of mast cells and RNA sequencing by linkage analysis of the exome sequence
- Elevated basal serum level tryptase associated with multisystem disorder, with joint hypermobility




- Not all individuals fulfilled criteria for hEDS.
- Relatively common in general population.

# Candidate 4:



- Studied population of 24 patients
- Skin biopsy analysed by TEM and Tenascin-X encoding region sequenced
- Large ECM protein, responsible for collagen I deposition and maintaining homeostasis of ECM




TNXB



- Tre substitutions:
  - Arg29Try
  - Val1195Met
  - Leu4033Ile





## Current working models

Mouse models of EDS

Still working on the hEDS mouse model.

# Current treatment

- Prevent and treat the symptoms:
- Physical therapy
  - Exercises
  - Posture reeducation
  - Osteopathic manipulative treatment
- Occupational therapy
  - Aids
  - Pain management strategies
- Acupuncture
- Dietary modifications
- Drugs
  - Antihistamine, mab
  - Anti-inflammatory
- Surgery





## The Ehlers-Danlos Syndromes

Ehlers-Danlos syndrome (EDS) is a group of genetic connective tissue disorders characterized by joint hypermobility, skin hyper-extensibility, and tissue fragility. There is phenotypic and genetic variation among the 14 subtypes. Professor Rodney Graham, a lead EDS expert, once said "No other condition in the history of modern medicine has been neglected in such a way as Ehlers-Danlos Syndrome."

**The Norris lab is ready to change that.**

# Current EDS Initiatives

18

Speaker

01

## EDS/HSD Survey

EDS and HSD are related to a wide array of comorbid conditions, but comprehensive clinical overviews of these conditions are lacking in scientific literature. We are gathering a large data set of the multisystemic problems related to EDS and HSD to inform the direction of future research studies of EDS and HSD at the Norris Lab and beyond.



02

## hEDS Genetic Registry

The Norris lab seeks to advance the understanding of hEDS through cutting-edge research into the genetic factors that underlie this complex condition. Through our comprehensive genetic registry and collaborative research efforts, we hope to improve diagnosis and treatment for individuals living with hEDS.



03

## Ehlers-Danlos Mouse Models

Using state of the art CRISPR-Cas9 mediated genome editing, the Norris lab is working to develop mouse models of every subtype of Ehlers-Danlos. To advance the research into these diseases, we plan to make these mouse models available to other research institutions at no charge.



04

## Patient-Scientist Initiative

The Norris lab believes that patients are the experts in their own diseases and has pioneered the "patient scientist" model of research. We offer multiple opportunities for students with hEDS who have an interest in research or medicine to gain experience in the lab.





Personnalized medicine



Identification of the mutation and biomarkers




Understanding fundamentals principles of syndrom



Diagnostic tools based on chemical/molecular manifestations  
more than clinical symptoms



Effective or curative therapeutics





1. Parapia L.A, Jackson C. (2008), Ehlers-Danlos syndrome – a historical review. *British Journal of Haematology*, 141: 32-35. <https://doi.org/10.1111/j.1365-2141.2008.06994.x>
2. Malfait F. & co. (2017), The 2017 international classification of the Ehlers-Danlos syndromes. *Am J Med Genet Part C Semin Med Genet*, 175C: 8-26. <https://doi.org/10.1002/ajmg.c.31552>
3. Wikipédia (2024), Ehlers-Danlos syndromes. Lastly edited 21.01.24. [https://en.wikipedia.org/wiki/Ehlers%20%93Danlos\\_syndromes](https://en.wikipedia.org/wiki/Ehlers%20%93Danlos_syndromes)
4. Demmler J.C & co. (2019), Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. *BMJ Open*, 9: 11. <https://doi.org/10.1136/bmjopen-2019-031365>
5. Deshmukh S.N. & co. (2016), Enigmatic insight into collagen. *J Oral Maxillofac Pathol*, 20(2):276-83. <https://doi.org/10.4103/0973-029X.185932>
6. Wikipédia (2024), Connective tissue. Lastly edited 20.01.24. [https://en.wikipedia.org/wiki/Connective\\_tissue](https://en.wikipedia.org/wiki/Connective_tissue)
7. Gensemer C. & co. (2021), Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. *Developmental Dynamics*, 250: 318-344. <https://doi.org/10.1002/dvdy.220>
8. Riley B. (2020), The Many Facets of Hypermobile Ehlers-Danlos Syndrome. *Journal of Osteopathic Medicine*, 120(1):30-32. <https://doi.org/10.7556/jaoa.2020.012>
9. Vandersteen A.M. & co. (2023), Genetic complexity of diagnostically unresolved Ehlers-Danlos syndrome. *BMJ J Med Genet*. <http://dx.doi.org/10.1136/jmg-2023-109329>
10. Igharo D. & co. (2022), Skin biopsy reveals generalized small fibre neuropathy in hypermobile Ehlers-Danlos syndrome. *Eu Journal of Neurology*, 30(3):719-728. <https://doi.org/10.1111/ene.15649>
11. Narcisi P. & co. (1994), A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. *Hum Mol Genet*, 3(9):1617-1620. <https://doi.org/10.1093/hmg/3.91617>
12. Syx D. & co. (2015), Ehlers-Danlos Syndrome, Hypermobility Type, Is Linked to Chromosome 8p22-8p21.1 in an Extended Belgian Family. *Hindawi Disease Markers*, 2015:9. <https://dx.doi.org/10.1155/2015/828970>

13. Lyons J.J. & co. (2016), Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. *Nat Genet.* 48(12):1564-1569. <https://doi.org/10.1038/ng.3696>
14. Zweers M.C. and co. (2005), Elastic fiber abnormalities in hypermobile type Ehlers-Danlos syndrome patients with tenascin-X mutations. *Wiley Clinical Genetics*, 67(4):330-334. <https://doi.org/10.1111/j.1399-0004.2005.00401.x>
15. The Norris Lab (2023), Ehlers-Danlos Syndrome Research. <https://www.thenorrislab.com/eds>
16. Cantu L. (2021), MUSC researchers announce gene mutation discovery associated with EDS. *MUSC Catalyst News*. <https://web.musc.edu/about/news-center/2021/07/14/musc-researchers-announce-gene-mutation-discovery-associated-with-eds-ehlers-danlos>
17. Reyhler G. & co. (2021), Physical therapy treatment of hypermobile Ehlers-Danlos syndrome: A systematic review. *American Journal of Medical Genetics Part A*, 185A:2986.2994. <https://doi.org/10.1002/ajmg.a.62393>
18. Perera H. (2023), Enhancing Quality of Life: How Occupational Therapy Can Aid Ehlers Danlos Syndrome. *LIFEWORKS OCCUPATIONAL THERAPY*. <https://lifeworksot.com.au/enhancing-quality-of-life-how-occupational-therapy-can-aid-ehlers-danlos-syndrome/#:~:text=Empowering%20individuals%20with%20EDS%20to,%2C%20and%20self%2Dcare%20techniques>.
19. Tudini F. & co. (2023), Evaluating the effects of two different kinesiology taping techniques on shoulder pain and function in patients with hypermobile Ehlers-Danlos syndrome. *Front Pain Res(Lausanne)*, 16(4):1089748. <https://doi.org/10.3389/fpain.2023.1089748>
20. CNN health (2023), Millions have the same «bendy body» disease as my daughter. Why isn't the medical profession paying more attention?. <https://edition.cnn.com/2022/12/24/health/hypermobile-ehlers-danlos-syndrome-health-hnk-spc-dst-intl/index.html>
21. Halverson C.M.E. and co. (2023), Clinician-associated traumatization from difficult medical encounters: Results from a qualitative interview study on the Ehlers-Danlos Syndromes. *Elsevier SSm Qualitative Research in Health*, 3:100237. <https://doi.org/10.1016/j.ssmqr.2023.100237>